Proteomics International Laboratories Launches $6m IPO
News Nov 28, 2014
Emerging life science company Proteomics International Laboratories Ltd is pleased to announce that it has launched its prospectus for a new IPO to raise up to $6 million via the issue of 30 million shares at 20c each.
The minimum subscription amount is $4 million.
PIQ is a specialist technology-driven life sciences company founded in 2001 and based in Perth, Australia. It is an established, revenue generating business with a focus on the area of proteomics, and has generated gross income of $7.5 million to date.
The Company’s business model is based on its proprietary technology platform which operates across three synergistic business units in massive growth markets;
1. Analytical services - Specialist contract research, analytical testing and consultancy - fee for service model. Proteomics market estimated to be worth $20.8b by 2018.
2. Diagnostics - Biomarkers of disease and personalised medicine - focus on diabetic kidney disease and Alzheimer's disease. Biomarkers market estimated to be worth $40.8b by 2018.
3. Therapeutics - Peptide drug discovery from venoms with a focus on painkillers and antibiotics. Peptide therapeutics market currently estimated to be worth $17b.
The synergy arises from PIQ’s technology platform, which can be applied to each unit simultaneously. The output from each can feed development and growth in the others. This maximises the opportunity for the Company to use its resources to generate revenue and create new intellectual property - which in turn can be sold, licensed, or retained to generate further revenues.
The proceeds of the IPO will be used to expand and accelerate the growth of each business unit.
Strong Immune Response in Diseased Corals Potential Trade-OffNews
Researchers have found a correlation between a strong immune response in diseased corals and a lower expression of genes associated with growth and reproduction.READ MORE